So, two days in a row I'll hit you with news of drugs to assist in immunotherapy. Yesterday it was about a company and its drug which failed. Today it's about one which impressed Regeneron with a late-breaker at AACR so much that it only took 11 days for a buyout offer to be made. Here's about their abstract: https://finance.yahoo.com/news/checkmate-pharmaceuticals-presents-clinical-trial-170100905.html
So yesterday it closed at $2.43 and today it's at $10.43. Again, assisting checkpoint inhibitors is an area with a lot of interest and anything which appears to work will be pursued by big pharma.
In case you're not following, the relevance is to EVT801.
KZA Price at posting:
$1.06 Sentiment: Buy Disclosure: Held
